Dr. Christoph Huber

Christoph Huber was Ugur Sahin's mentor and scientific collaborator who co-founded Ganymed Pharmaceuticals in 2001 alongside Sahin and Tureci. At Ganymed, Huber contributed to the development of zolbetuximab, the monoclonal antibody that demonstrated significant survival benefit in gastric cancer and led to Astellas Pharma's $436+ million acquisition in 2016. Huber's scientific expertise in antibody development and translational medicine provided the technical foundation for BioNTech's early platform work, though he has maintained a lower public profile than Sahin and Tureci in the company's subsequent growth.

Dr. Christoph Huber is a scientific co-founder of BioNTech SE and was previously a co-founder of Ganymed Pharmaceuticals alongside Ugur Sahin and Ozlem Tureci in 2001. At Ganymed, Huber contributed to the development of zolbetuximab, a monoclonal antibody targeting CLDN18.2 for gastric and esophageal cancers, which demonstrated significant overall survival benefit in randomized trials and led to the company's acquisition by Astellas Pharma in 2016 for over $436 million. Huber's expertise in antibody development and translational oncology research informed BioNTech's early technology platform decisions, including the initial focus on multiple therapeutic modalities beyond mRNA. While maintaining a lower public profile than Sahin and Tureci, Huber's scientific contributions were instrumental in establishing the research culture and technical capabilities that enabled BioNTech's later success.